Share this article
Share this article
ResearchAndMarkets.com s offering.
The Global Clinical Trials Market was valued at USD51.25 billion in 2020 and is anticipated to reach USD77.20 billion by 2026, registering a CAGR of 7.10% in the next five years.
The market is driven by the outbreak of tropical and infectious diseases such as COVID-19, which has led to extensive clinical trials around the world in order to find the suitable treatment and vaccine.
Also, the digitization of clinical trials is anticipated to propel the growth of this market in the coming years.
Additionally, the increasing prevalence of chronic diseases and growing need for personalized drugs are some other key factors propelling the growth of the Global Clinical Trials Market. Governments in various economies are also providing favorable support for clinical trials in order to find the cure for deadly diseases like coronavirus. The increasing expenditure on R&D activities and rise in biotechnology firms i
Share this article
Share this article
ResearchAndMarkets.com s offering.
The global clinical oncology next generation sequencing market is expected to grow from $0.44 billion in 2020 to $0.56 billion in 2021 at a compound annual growth rate (CAGR) of 27.3%.
Major players in the clinical oncology next generation sequencing market are Thermo Fisher Scientific (Qiagen), Oxford Nanopore Technologies, QIAGEN, Myriad Genetics, Illumina, F. Hoffmann-La Roche, Perkin Elmer, Agilent Technologies, Pacific Bioscience, and Caris Life Sciences.
The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $1.05 billion in 2025 at a CAGR of 17%.
Transient Protein Expression Market is expected to reach US$ 983.10 million by 2027 With THERMO FISHER SCIENTIFIC INC.; MERCK KGaA; QIAGEN; GenScript; Promega Corporation; Takara Bio Inc.;
iCrowd Newswire
08 May 2021, 13:33 GMT+10
According to The Insight Partners market research study titled Transient Protein Expression Market to 2027 – COVID-19 Impact and Global Analysis – by Product Type, Application, and End User, the global transient protein expression market is expected to reach US$ 983.10 million by 2027 from US$ 660.00 million in 2019. The market is estimated to grow at a CAGR of 5.3% from 2020 to 2027. The report highlights the trends prevalent in the global transient protein expression market and the factors driving the market along with those that act as deterrents to its growth.
Share this article
Share this article
ResearchAndMarkets.com s offering.
As mentioned in this research report, the global market for clinical trial management is likely to register growth at a CAGR of 10.92% over the period of 2021-2028.
Factors such as an alarming rise in chronic diseases, a surge in R&D activities in the medical sector, and benefits offered by CTM software are stimulating the growth of the reviewed market over the forecasted period. Additionally, the increase in clinical trials is opening new avenues for the market during the registered period.
However, concerns regarding the security of CTM systems, along with the high initial cost of implementation, are limiting the global market s growth. The high costs of installing and maintaining CTM software have made the researchers and pharmaceutical companies rethink investing in these systems, obstructing the market s progress.
Share:
ResearchAndMarkets.com s offering.
As mentioned in this research report, the global market for clinical trial management is likely to register growth at a CAGR of 10.92% over the period of 2021-2028.
Factors such as an alarming rise in chronic diseases, a surge in R&D activities in the medical sector, and benefits offered by CTM software are stimulating the growth of the reviewed market over the forecasted period. Additionally, the increase in clinical trials is opening new avenues for the market during the registered period.
However, concerns regarding the security of CTM systems, along with the high initial cost of implementation, are limiting the global market s growth. The high costs of installing and maintaining CTM software have made the researchers and pharmaceutical companies rethink investing in these systems, obstructing the market s progress.